


BPH Surgery Reimagined  
**AQUABLATION**<sup>®</sup>  
Therapy by PROCEPT BioRobotics



## PROSTATES COME IN ALL SIZES & SHAPES




\*Size-Independent  
References in Appendix



**PRIORITIZE  
SYMPTOM  
RELIEF**

**PRIORITIZE  
SEXUAL  
FUNCTION &  
CONTINENCE  
PRESERVATION**

**AQUABLATION®**



Visualization of the entire prostate for customized treatment planning



Robotic execution for predictable and reproducible resection




Minimize variables that impact outcomes

Aquablation therapy provides long term symptom relief with low rates of complications


1. Gilling P, et al. Three-year outcomes after Aquablation® therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020 Feb;27(1):10072-10079.  
2. Desai M, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Canadian Journal of Urology. 27(2):10147-10153. Apr 2020.  
3. Bach T, et al. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med. 2020 Feb;9(2): 603.

### SIMULTANEOUS IMAGING



Visualization of the entire prostate through cystoscope and ultrasound

### INTRAOPERATIVE SURGICAL PLANNING




Identify critical anatomy and customize resection contour

# CONSISTENCY

ROBOTIC EXECUTION FOR PREDICTABLE AND REPRODUCIBLE RESECTION

## SIZE AND SHAPE-INDEPENDENT RESECTION

Average resection time = 5.8 minutes




Gilling P, et al. Three-year outcomes after Aquablation® therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020 Feb;27(1):10072-10079.  
Desai M, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Canadian Journal of Urology. 27(2):10147-10153. Apr 2020.

### LOW RATES OF IRREVERSIBLE COMPLICATIONS

SAFETY OUTCOMES	WATER & WATER II (30-150mL)	OPEN WATER (20-150mL)
Continence Preservation	99%	99%
Erectile Function Preservation	100%	100%
Ejaculatory Function Preservation	86%	92%


### SYMPTOM RELIEF

Average IPSS improvement = 16 points



### FLOW IMPROVEMENT

Average Qmax improvement = 11 mL/sec



Gilling P, et al. Three-year outcomes after Aquablation® therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020 Feb;27(1):10072-10079.  
Desai M, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Canadian Journal of Urology. 27(2):10147-10153. Apr 2020.  
Bach T, et al. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med. 2020 Feb;9(2): 603.

# AQUABLATION THERAPY PROCEDURE | ANIMATION




Note: Animation does not represent full draping required during Aquablation therapy.

# AQUABLATION THERAPY RESULTS

**BEFORE**


Obstructed Prostatic Urethra



3 months  
post-op




Intraoperative  
ultrasound



**AFTER**

Open Prostatic Urethra

# PROSTATES SKEW LARGE AND HAVE COMPLEX ANATOMY



**AQUABLATION®**  
UNIQUELY SUITED TO TREAT  
ALL GLANDS OVER 50 mL

Gilling P, et al. Three-year outcomes after Aquablation® therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020 Feb;27(1):10072-10079.  
Desai M, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Canadian Journal of Urology. 27(2):10147-10153. Apr 2020.  
Bach T, et al. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med. 2020 Feb;9(2): 603.  
Commercial data from PROCEPT BioRobotics

## KEY CLINICAL STUDIES



Only FDA pivotal study randomized to TURP, the gold standard



Only successful FDA multicenter study for large prostates



Largest commercial study evaluating safety and efficacy



## AQUABLATION THERAPY

SAFE and EFFECTIVE

The only size and shape independent BPH solution without compromise

## SURGICAL PRACTICE GUIDELINES



American Urological Association



European Association of Urology



Canadian Urological Association

**NICE** National Institute for Health and Care Excellence

## ~100 PUBLICATIONS IN TOP UROLOGY JOURNALS




IMPACT FACTOR 17.298



5.157




4.524



3.029


1. Gilling P. et al. Three-year outcomes after Aquablation® therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020 Feb;27(1):10072-10079.  
 2. Desai M, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Canadian Journal of Urology. 27(2):10147-10153. Apr 2020.  
 3. Bach T. et al. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med. 2020 Feb;9(2): 603.  
 Aquablation therapy provides long term symptom relief with low rates of complications<sup>1,2,3</sup>  
 Publication count – PubMed search on December 15, 2020

# REIMBURSEMENT LANDSCAPE



AMA Current Procedural Terminology (CPT) Manual-2020  
 CMS-1736-FC CY 2021 Medicare Program: Hospital Outpatient Prospective Payment- Notice of Final Rulemaking with Comment Period (NFRM);  
 CY 2021 Medicare Hospital Outpatient Prospective Payment System (CMS-1736-FC) Addendum B  
 CMS-1735-F Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2021 Rates  
 IPPS FY 2021 Final Rule Tables and Correction Notice Tables; table 1A-1E, table 5  
 ICD-10-PCS Codebook 2021

# 2021 OUTPATIENT PAYMENT RATES



AMA Current Procedural Terminology (CPT) Manual-2020  
CMS-1736-FC CY 2021 Medicare Program: Hospital Outpatient Prospective Payment- Notice of Final Rulemaking with Comment Period (NFRM);  
CY 2021 Medicare Hospital Outpatient Prospective Payment System (CMS-1736-FC) Addendum B

**PROSTATES COME IN ALL SIZES & SHAPES**

**PRIORITIZE**  
SEXUAL  
FUNCTION &  
CONTINENCE  
PRESERVATION

SYMPTOM  
RELIEF



**NON-RESECTIVE**

**CONSTRAINTS**

- Minimal symptom relief
- May require retreatment
- Size & shape limitations

**70%** Men feel BPH surgery requires a tradeoff between safety & efficacy



**small**  
(30-40mL)



**medium**  
(40-80mL)



**large**  
(80-150mL)



**extra large**  
(150mL+)

TURP & GreenLight

Enucleation\* & Simple

UroLift & Rezum

**AQUABLATION®**  
THE ONLY SIZE & SHAPE  
INDEPENDENT BPH SOLUTION  
WITHOUT COMPROMISE

**PRIORITIZE**  
SYMPTOM  
RELIEF



SEXUAL  
FUNCTION &  
CONTINENCE  
PRESERVATION

**RESECTIVE**

**CONSTRAINTS**

- Time intensive & learning curve
- Variable complication rate
- Size & shape limitations

Men are not willing to sacrifice sexual function for symptom relief

**82%**

\*Size-Independent  
References in Appendix

# AQUABLATION®

Therapy by PROCEPT BioRobotics

## **RISK AND SAFETY INFORMATION**

All surgical treatments have inherent and associated side effects. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. For more information about potential side effects and risks associated with Aquablation therapy, speak with your urologist or surgeon. No claim is made that the AQUABEAM® Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required. For more detailed information on risks, side effects, and contraindications refer to the IFU.

### **Indications for Use: United States, Canada, and Hong Kong**

The AQUABEAM® Robotic System is intended for the resection and removal of prostate tissue in males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.

### **Indications for Use: Rest of World**

The AQUABEAM® Robotic System is intended for the resection and removal of prostate tissue in males suffering from lower urinary tract symptoms.

**AQUABLATION<sup>®</sup>**  
Therapy by PROCEPT BioRobotics

# Appendix

# CLINICALLY PROVEN OUTCOMES



**OUTCOMES**

Superior safety and non-inferior efficacy compared to TURP  
Sub-group of prostates over 50 mL were SUPERIOR in safety AND efficacy over TURP

Safe and effective without significant increase in procedure or resection time

Safe and effective without significant increase in procedure or resection time

**DESCRIPTION**

Only FDA pivotal study randomized to the gold standard

Only successful FDA multicenter study for large prostates

Largest commercial trial evaluating safety and efficacy

**DESIGN**

Prospective, double-blind, randomized controlled clinical trial

Prospective, multicenter clinical trial

Prospective, multicenter, all-comer trial

**POPULATION**

Prostates 30 – 80 mL  
N = 181  
17 Sites | US, UK, AU, NZ

Prostates 80 – 150 mL  
N = 101  
16 Sites | US and CA


Prostates 20 – 150 mL  
N = 178  
6 Sites | DE, AU, NZ, UK, LB

Gilling P. et al. Three-year outcomes after Aquablation® therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020 Feb;27(1):10072-10079

Desai M, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Canadian Journal of Urology. 27(2):10147-10153. Apr 2020

Bach T. et al. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med. 2020 Feb;9(2): 603.

# AQUABLATION THERAPY PROCEDURE | VIDEO




## HEMOSTASIS METHOD

- Clot Evacuation
- Removal of “fluffy tissue”
- Focal bladder-neck cautery
- Continuous bladder irrigation




## RESULTS

- In **1,116** Aquablation therapy procedures
- Across prostates ranging from **20 to 300 mL**
- Aquablation therapy with focal bladder-neck cautery had a **0.6% transfusion rate**



FLUFFY TISSUE



USE LOOP TO REMOVE  
FLUFFY TISSUE



FOCAL CAUTERY  
AT BLEEDERS

# BPH LANDSCAPE SLIDE REFERENCES

- Prostate size range: Data on file at PROCEPT BioRobotics
- Application of BPH Technology for certain size ranges
  - AUA Guidelines: Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (2018, amended 2019, 2020) Published 2018, Amended 2019, 2020
- Resecting Claims
  - Sonksen, J, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol.* 2015 Oct;68(4):643-52.
  - Westwood, J, et al. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. *Ther Adv Urol.* 2018 Nov; 10(11): 327–333.
  - Urology Care Foundation, The Official Foundation of the American Urological Association. Accessed Dec 2019. [https://www.urologyhealth.org/urologic-conditions/benign-prostatic-hyperplasia-\(bph\)](https://www.urologyhealth.org/urologic-conditions/benign-prostatic-hyperplasia-(bph))
- Non-Resecting Claims
  - Westwood, J, et al. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. *Ther Adv Urol.* 2018 Nov; 10(11): 327–333.
  - Delay, KJ, et al. Ejaculatory dysfunction in the treatment of lower urinary tract symptoms. *Transl Androl Urol.* 2016 Aug; 5(4): 450–459.
  - Leong, JY. Minimizing Sexual Dysfunction in BPH Surgery. *Curr Sex Health Rep.* 2019 Sep; 11(3): 190–200.
  - Bachmann, A, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial—the GOLIATH study. *Eur Urol.* 2014 May;65(5):931-42
  - Sapetti, J, et al. Urinary incontinence after HoLEP: Incidence, evolution and predictive factors. *Prog Urol.* 2019 Feb;29(2):101-107
  - Michalak, J, et al. HoLEP: the gold standard for the surgical management of BPH in the 21st century. *Am J Clin Exp Urol.* 2015; 3(1): 36-42.
  - Khera, M. Simple Prostatectomy. *Medscape.* 2018. <https://emedicine.medscape.com/article/445996-print>
- Patient opinion on trade-off
  - Reference for 70% and 82% is Bouhadana, et al. Patient Perspectives on Benign Prostatic Hyperplasia Surgery: A Focus on Sexual Health. *J Sex Med* 2020;1 – 5

**AQUABLATION**<sup>®</sup>  
Therapy by PROCEPT BioRobotics

900 Island Drive, Suite 210 / Redwood City, CA 94065 / [PROCEPT-BioRobotics.com](https://www.procept-biorobotics.com)